MX2018002510A - Combinacion farmaceutica para trastornos del estado de animo. - Google Patents

Combinacion farmaceutica para trastornos del estado de animo.

Info

Publication number
MX2018002510A
MX2018002510A MX2018002510A MX2018002510A MX2018002510A MX 2018002510 A MX2018002510 A MX 2018002510A MX 2018002510 A MX2018002510 A MX 2018002510A MX 2018002510 A MX2018002510 A MX 2018002510A MX 2018002510 A MX2018002510 A MX 2018002510A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
mood disorders
pharmaceutical composition
melatonin
ketamine
Prior art date
Application number
MX2018002510A
Other languages
English (en)
Inventor
Acacia BENÍTEZ KING Gloria
Trueta Segovia Citlali
VALDÉS TOVAR Marcela
Daniel Quero Chávez Brian
María Dorantes Barrón Ana
Estrada Reyes Rosa
Lucia Dubocovich Jerkovich Margarita
Original Assignee
Instituto Nac De Psiquiatria Ramon De La Fuente Muniz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Psiquiatria Ramon De La Fuente Muniz filed Critical Instituto Nac De Psiquiatria Ramon De La Fuente Muniz
Priority to MX2018002510A priority Critical patent/MX2018002510A/es
Publication of MX2018002510A publication Critical patent/MX2018002510A/es
Priority to US16/976,636 priority patent/US20210046049A1/en
Priority to PCT/MX2019/000023 priority patent/WO2019168396A1/es
Priority to US18/351,665 priority patent/US20230414568A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación sinérgica de un agente antagonista del receptor NMDA, como lo es el principio activo: ketamina y un agente agonista de los receptores de melatonina MT1 y MT2, como lo es el principio activo: melatonina, los cuales se encuentran en una composición farmacéutica, misma que está indicada para el control y tratamiento de enfermedades psiquiátricas.
MX2018002510A 2018-02-28 2018-02-28 Combinacion farmaceutica para trastornos del estado de animo. MX2018002510A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2018002510A MX2018002510A (es) 2018-02-28 2018-02-28 Combinacion farmaceutica para trastornos del estado de animo.
US16/976,636 US20210046049A1 (en) 2018-02-28 2019-02-28 Pharmaceutical combination for mood disorders
PCT/MX2019/000023 WO2019168396A1 (es) 2018-02-28 2019-02-28 Combinación farmacéutica para trastornos del estado de ánimo
US18/351,665 US20230414568A1 (en) 2018-02-28 2023-07-13 Pharmaceutical combination for mood disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018002510A MX2018002510A (es) 2018-02-28 2018-02-28 Combinacion farmaceutica para trastornos del estado de animo.

Publications (1)

Publication Number Publication Date
MX2018002510A true MX2018002510A (es) 2018-10-10

Family

ID=64605493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002510A MX2018002510A (es) 2018-02-28 2018-02-28 Combinacion farmaceutica para trastornos del estado de animo.

Country Status (3)

Country Link
US (2) US20210046049A1 (es)
MX (1) MX2018002510A (es)
WO (1) WO2019168396A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法

Also Published As

Publication number Publication date
US20230414568A1 (en) 2023-12-28
WO2019168396A1 (es) 2019-09-06
US20210046049A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
EA201690033A2 (ru) Морфинановые соединения
MX2007008328A (es) Antagonistas cxcr4 para el tratamiento de trastornos medicos.
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
EP3856182A4 (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
IN2014DN09571A (es)
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2023005408A (es) Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.
MX2022007391A (es) Compuestos activos frente a receptores nucleares.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2018002510A (es) Combinacion farmaceutica para trastornos del estado de animo.
AU2014287427B2 (en) Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2019013666A (es) Composiciones farmacéuticas de liberación modificada de huperzina y métodos para usarlas.
PH12021550671A1 (en) Prodrugs of cgrp antagonists